Indian generics giant Lupin Limited faced “another difficult quarter… despite some good developments” in Q3, said non-executive vice chairman Kamal Sharma on a company earnings call. Residual metformin returns from retail and provision for aged stock returns of oseltamivir saw gross profit margins fall, but a series of promising impending launches could boost the company’s fortunes.
Lupin managing director Nilesh Gupta said: “We are on the path of sustained growth across markets. Our inhalation portfolio continues...
